AZ/Merck’s Lynparza approved by SMC to treat advanced prostate cancer in Scotland
Up to 20% of prostate cancer cases are classified as castration-resistant
Read More
Tag: olaparib
Institute of Cancer Research embraces olaparib recommendation
Vital AstraZeneca therapy may transform lives of people with certain breast and prostate cancers
Read More
Lynparza shows promise in preventing cancer recurrence
Lynparza is the first medicine targeting BRCA mutations to show clinical benefit in adjuvant setting
Read More
EU nod for Lynparza in pancreatic cancer
The drug is the only PARP inhibitor approved in this disease
Read More
Lynparza backed by CHMP for BRCA-mutated pancreatic cancer
Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ
Read More
US nod for Lynparza in HRD-positive advanced ovarian cancer
Lynparza has been cleared for use as a first-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
Read More
AZ/MSD’s Lynparza shows survival benefit in prostate cancer patients
Results from the PROfound trial showed a statistically significant and clinically meaningful improvement in overall survival
Read More
SMC green light for rare blood cancer treatment
NHS funding was backed for four medicines
Read More
Continued success for Lynparza in ovarian cancer
The drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months.
Read More
Lynparza bags positive prostate cancer results
The drug more than doubled median radiographic progression-free survival.
Read More
Lynparza hits target in late stage ovarian cancer trial
he companies announced earlier this month that the drug was also successful in prostate cancer.
Read More
‘Unprecedented’ results in AZ’ late-stage Lynparza trial
The results were announced at the 2019 ASCO meeting.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
